Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

BACKGROUND: CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety result...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanriover, Mine Durusu, Doğanay, Hamdi Levent, Akova, Murat, Güner, Hatice Rahmet, Azap, Alpay, Akhan, Sıla, Köse, Şükran, Erdinç, Fatma Şebnem, Akalın, Emin Halis, Tabak, Ömer Fehmi, Pullukçu, Hüsnü, Batum, Özgür, Şimşek Yavuz, Serap, Turhan, Özge, Yıldırmak, Mustafa Taner, Köksal, İftihar, Taşova, Yeşim, Korten, Volkan, Yılmaz, Gürdal, Çelen, Mustafa Kemal, Altın, Sedat, Çelik, İlhami, Bayındır, Yaşar, Karaoğlan, İlkay, Yılmaz, Aydın, Özkul, Aykut, Gür, Hazal, Unal, Serhat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266301/
https://www.ncbi.nlm.nih.gov/pubmed/34246358
http://dx.doi.org/10.1016/S0140-6736(21)01429-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266301/
https://www.ncbi.nlm.nih.gov/pubmed/34246358
http://dx.doi.org/10.1016/S0140-6736(21)01429-X

Ejemplares similares